Comprehensive analysis of orbital lymphoma in a Turkish cohort: clinical characteristics, histological subtypes, treatment modalities, prognostic factors, and implications for management.

Autor: Akyildiz A; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Ismayilov R; Department of Internal Medicine, Hacettepe University Medical School, Ankara, Turkey. ismayilov_r@hotmail.com., Rustamova N; Department of Ophthalmology, Hacettepe University Medical School, Ankara, Turkey., Tokatli M; Department of Internal Medicine, Hacettepe University Medical School, Ankara, Turkey., Koc I; Department of Ophthalmology, Hacettepe University Medical School, Ankara, Turkey., Akin S; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Kiratli H; Department of Ophthalmology, Hacettepe University Medical School, Ankara, Turkey., Barista I; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Annals of hematology [Ann Hematol] 2024 Mar; Vol. 103 (3), pp. 905-915. Date of Electronic Publication: 2023 Dec 07.
DOI: 10.1007/s00277-023-05569-9
Abstrakt: The study analysed the clinical characteristics, treatment approaches, and survival outcomes of 97 consecutive patients with orbital lymphoma (OL) over a 25-year period at. The median age of the patients was 57.6 years, and 59.8% (n = 58) were male. Marginal zone lymphoma constitutes the most prevalent subtype, accounting for 67% of cases, whereas other common subtypes include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, and T-cell lymphomas. Unilateral involvement was observed in the majority of cases (72.3%). Common clinical presentations included mass (30.9%), swelling (26.8%), and epiphora (11.3%). Of the patients, 7.2% received rituximab alone, 14.4% received radiotherapy alone, 48.5% received chemotherapy, 27.8% received radiotherapy plus rituximab, 22.7% received radiotherapy plus chemotherapy, and 5.2% underwent surgery as the first-line treatment. During a median follow-up of 4.3 years, 15.5% of patients experienced relapse or disease progression. The 5-year and 10-year progression-free survival rates were 84.1% and 79.1%, respectively. This study contributes to our understanding of OLs and provides a foundation for further investigations in this field. Male gender, presence of B symptoms, advanced stage, secondary orbital lymphoma, aggressive histological subtype, and elevated serum lactate dehydrogenase levels were associated with poorer (either inferior or worse) progression-free survival.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: